NEW YORK, Jan. 13, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against TerraVia Holdings, Inc. (“TerraVia” or the “Company”) (NASDAQ:TVIA) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Arrowhead securities between August 8, 2016 and November 7, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/tvia.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) TerraVia’s products caused gastrointestinal problems, including nausea and vomiting; and (2) consequently, Defendants’ statements about TerraVia’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times.
On November 7, 2016, Bloomberg broadcasted a news report, “Soylent Thinks It Found What Was Making People Sick: Algae.” The article described how Soylent, Rosa Foods, Inc.’s meal replacement drink, includes an algal flour ingredient provided by TerraVia. This ingredient has caused Soylent consumers to become sick and Rosa Foods said it will remove the ingredient by early 2017. Mark Brooks, TerraVia’s Senior Vice President denied that the Company’s algal flour was responsible for making consumers sick, however Bloomberg added that TerraVia had sent a letter in July to EN-R-G Foods, LLC, a separate customer, warning that TerraVia’s algal protein ingredient had been linked to a "modest number of reports" with similar complaints and ailments, like nausea and vomiting, connected with EN-R-G’s Honey Stinger energy bar. Following this news, TerraVia stock dropped $0.15 per share, or 8.11%, to close at $1.70 on November 7, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/tvia or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in TerraVia you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



